Verastem, Inc.
VSTM
Jodie situation report
Verastem, Inc.'s move is being confirmed by its market group.
No new filing conclusion is available. 23 of 24 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 14 directly disclosed connections are confirming.
- At least 16 of 24 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as XNCR begins moving with the group.
Invalidation: The live read weakens if participation falls to 8 of 24 members or fewer.
Who this business touches
The relationships behind VSTM
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
PFEPfizer, Inc.supplierMar 4, 2026 ▾
“Pfizer provided us with an initial quantity of clinical supplies of one of the products for an agreed upon price.”
IQVIQVIA Holdings Inc.partnerMay 7, 2026 ▾
“Vendor Financing Arrangement The Company and IQVIA, Inc.”
ABBVAbbVie Inc.competitorMar 4, 2026 ▾
“Competitors that are currently developing RAF and/or MEK inhibitors are Abbvie, AstraZeneca, Bristol Myers Squibb Company, Erasca, Genentech, Novartis AG, and Pfizer.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 11 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
VSTM is currently a Participant in the organic co-movement group Rare Disease Biotech. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.